PT. Cahaya Putra Mandiri
FDA import alert and refusal historyJakarta, IndonesiaFEI 3007108505
As of October 26, 2026, PT. Cahaya Putra Mandiri (Jakarta, Indonesia) is on the red list of FDA Import Alert 16-81 (Seafood products: Salmonella) for octopus, published by FDA on August 6, 2013, and has no FDA import refusals recorded since October 2016.
Data from FDA public records, last checked . Request a correction
Current status
- Import alerts
- IA 16-81 · red list
- Last import refusal
- None since October 2016
- Last warning letter
- None found
- Last inspection
- None on record
Every FDA record for PT. Cahaya Putra Mandiri
1 record, newest first. Each line links to the FDA page it came from.
2013
- Import alert listingListed on Import Alert 16-81red listOctopusSource
Questions about PT. Cahaya Putra Mandiri
- Is PT. Cahaya Putra Mandiri on an FDA import alert?
- Yes. As of October 26, 2026, PT. Cahaya Putra Mandiri is on the red list of FDA Import Alert 16-81, “Seafood products: Salmonella”, for octopus; FDA published the listing on August 6, 2013.
- Has FDA refused shipments from PT. Cahaya Putra Mandiri?
- No FDA import refusals for PT. Cahaya Putra Mandiri appear in FDA's refusal data since October 2016, as of October 26, 2026.
- What is PT. Cahaya Putra Mandiri's FEI number?
- PT. Cahaya Putra Mandiri's FDA Establishment Identifier (FEI) is 3007108505.
- Can shipments from PT. Cahaya Putra Mandiri still enter the U.S.?
- Shipments of octopus from PT. Cahaya Putra Mandiri can be detained without physical examination under Import Alert 16-81; FDA releases them only if evidence shows they do not have the listed violation. Importers must consider this listing in their FSVP evaluation (21 CFR 1.505).
Buying from PT. Cahaya Putra Mandiri?
Watch it and get the FDA record the day it changes. Free for one supplier.
SupplierRadar is not affiliated with the U.S. Food and Drug Administration. Data comes from public FDA records and may contain errors. This is not legal advice; importers remain responsible for their supplier evaluations.